Lonza Unveils Rapid Custom Media Prototyping Service (RaMP) to Drastically Accelerate Early Bioprocess Development Timelines

August 30, 2026

Outsourced Pharma Global

Overview

Lonza has launched its Rapid Media Prototyping Service (RaMP) to significantly shorten early bioprocess development timelines for biopharmaceutical companies. This service provides custom liquid and powder media in non-GMP batches with flexible sizes and swift turnaround times. It enables scientists to generate critical process data quickly, streamlining the transition to GMP manufacturing and accelerating therapeutic development.

In Depth

Key Findings

Lonza has introduced its innovative Rapid Media Prototyping Service (RaMP), designed to resolve a critical bottleneck in the early stages of biopharmaceutical development. This service aims to substantially accelerate the overall bioprocess development timeline by drastically reducing the lead time for custom media development. Consequently, biopharmaceutical companies can more swiftly identify optimal media compositions and progress to subsequent development phases.

Technical/Clinical Details

The RaMP service delivers custom-designed media, available in liquid or powder formats, tailored to specific cell line and process requirements. A key advantage of RaMP is its ability to supply small, non-GMP batches (typically a few liters to tens of liters) with a dramatically faster turnaround time—within weeks—compared to conventional custom media manufacturing. This allows R&D scientists to rapidly evaluate multiple media formulations and efficiently compare their impact on cell growth, protein productivity, and product quality. The wealth of data gathered at early stages facilitates more informed decision-making and reduces risks in later GMP manufacturing phases. RaMP is an integral part of Lonza’s broader strategy to bridge early formulation work with long-term scalability towards commercial-scale manufacturing.

Background & Context

Biopharmaceutical development heavily relies on complex cell culture processes, where media optimization directly impacts productivity, quality, and cost. Traditional custom media development often involves lengthy lead times and large minimum order quantities, hindering flexibility, especially in early development stages. Recognizing this challenge, major CDMOs like Lonza are providing faster, more agile solutions to accelerate innovation across the biopharmaceutical industry. This aligns with the increasing importance of media development, particularly with the emergence of new modalities such as cell and gene therapies.

Strategic Significance & Outlook

The introduction of the RaMP service is expected to significantly impact the efficiency and speed of biopharmaceutical development. By alleviating the media development bottleneck, more novel biopharmaceutical candidates can advance to clinical development more quickly. Ultimately, this will shorten the time it takes for patients to access innovative therapies. Lonza is anticipated to further strengthen its customer relationships and maintain leadership in biopharmaceutical manufacturing through this service. There is also potential for insights gained from RaMP to fuel further advancements in AI/Machine Learning-driven media design.

Source: https://www.outsourcedpharma.com/doc/lonza-launches-rapid-custom-media-prototyping-service-to-accelerate-early-bioprocess-development-0001

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.